Loading...
Loading...
NAMSW| Name | Value |
|---|---|
| Revenues | 29.1M |
| Cost of Revenue | 0.0M |
| Gross Profit | 29.1M |
| Operating Expense | 54.1M |
| Operating I/L | -25.0M |
| Other Income/Expense | 8.4M |
| Interest Income | 4.4M |
| Pretax | -16.6M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -16.6M |
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company specializing in developing treatments for metabolic diseases. Their lead investigational candidate, obicetrapib, is a selective inhibitor targeting the Cholesteryl Ester Transfer Protein (CETP), which has demonstrated the ability to reduce low-density lipoprotein cholesterol (LDL-C) and increase high-density lipoprotein cholesterol (HDL-C). The company's focus on developing novel therapies for metabolic diseases positions them to generate revenue through the successful development and commercialization of their innovative treatments.
